This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
risk factors | 1103 |
public health | 960 |
risk perception | 676 |
risk assessment | 671 |
increased risk | 508 |
risk management | 491 |
health care | 451 |
united states | 434 |
systemic risk | 405 |
systematic review | 398 |
risk factor | 388 |
infectious diseases | 384 |
high risk | 364 |
acute respiratory | 281 |
cohort study | 278 |
social distancing | 277 |
pregnant women | 256 |
risk communication | 243 |
cardiovascular disease | 225 |
infectious disease | 224 |
blood pressure | 222 |
cord uid | 217 |
doc id | 217 |
world health | 216 |
higher risk | 208 |
coronavirus disease | 206 |
mental health | 205 |
climate change | 205 |
risk perceptions | 201 |
severe covid | 198 |
respiratory syndrome | 195 |
health organization | 187 |
abstract background | 184 |
meat inspection | 184 |
health risk | 182 |
multiple sclerosis | 180 |
may also | 180 |
small ruminants | 179 |
novel coronavirus | 174 |
human rights | 174 |
severe acute | 174 |
food safety | 168 |
lyme disease | 162 |
machine learning | 161 |
acquired pneumonia | 160 |
general population | 159 |
decision making | 158 |
cardiovascular risk | 155 |
human health | 155 |
rheumatoid arthritis | 153 |
first trimester | 152 |
stock market | 148 |
logistic regression | 147 |
health risks | 147 |
heart failure | 146 |
risk analysis | 146 |
disease risk | 146 |
heart disease | 146 |
avian influenza | 145 |
physical activity | 139 |
low risk | 139 |
infection risk | 139 |
disease control | 139 |
breast cancer | 137 |
hand hygiene | 137 |
primary care | 134 |
animal health | 133 |
adverse events | 129 |
risk group | 129 |
statistically significant | 128 |
social risk | 124 |
diabetes mellitus | 123 |
intensive care | 120 |
control study | 120 |
occupational health | 118 |
infection control | 116 |
copyright holder | 113 |
made available | 112 |
food chain | 112 |
controlled trial | 112 |
united kingdom | 109 |
abcd study | 108 |
perceived risk | 108 |
author funder | 107 |
granted medrxiv | 107 |
veal calves | 107 |
care workers | 106 |
version posted | 105 |
developing countries | 105 |
stem cell | 100 |
clinical trial | 99 |
cancer risk | 99 |
respiratory tract | 99 |
factors associated | 99 |
financial crisis | 99 |
social media | 99 |
risk score | 97 |
transplant recipients | 96 |
supply chain | 94 |
age group | 94 |
adverse effects | 94 |
birth weight | 93 |
depressive symptoms | 92 |
drinking water | 92 |
myocardial infarction | 91 |
supply chains | 91 |
clinical trials | 91 |
neural network | 91 |
virus infection | 91 |
pandemic influenza | 91 |
international license | 89 |
healthcare professionals | 89 |
randomized controlled | 89 |
relative risk | 88 |
suicide risk | 88 |
least one | 88 |
cell cultures | 88 |
type diabetes | 87 |
total number | 87 |
vascular risk | 87 |
even though | 86 |
less likely | 86 |
emerging infectious | 86 |
potential risk | 86 |
health effects | 86 |
data collection | 85 |
new york | 85 |
age groups | 84 |
neural networks | 84 |
alcohol consumption | 84 |
one study | 83 |
global health | 83 |
risks associated | 83 |
may lead | 82 |
potential concern | 82 |
systemic risks | 82 |
among patients | 82 |
influenza virus | 82 |
ebola virus | 81 |
natural disasters | 81 |
health problems | 81 |
recent years | 81 |
risk assessments | 80 |
important role | 80 |
healthcare workers | 79 |
risk reduction | 79 |
escherichia coli | 79 |
control measures | 78 |
control group | 78 |
substance use | 78 |
case study | 77 |
zoonotic disease | 77 |
side effects | 76 |
clinical characteristics | 76 |
lung cancer | 74 |
vaccine safety | 74 |
crisis management | 74 |
immune system | 73 |
risk groups | 73 |
high levels | 73 |
peer review | 73 |
previous studies | 72 |
care unit | 72 |
health services | 72 |
clinical practice | 72 |
disaster risk | 72 |
disease severity | 71 |
cognitive impairment | 71 |
protective equipment | 71 |
avian flu | 71 |
influenza pandemic | 71 |
lower risk | 71 |
south africa | 71 |
risk associated | 71 |
mortem inspection | 70 |
animal welfare | 70 |
lung transplantation | 70 |
physical systems | 69 |
risk prediction | 69 |
family members | 69 |
hospitalized patients | 69 |
chronic disease | 69 |
confidence interval | 68 |
severe asthma | 68 |
mass index | 68 |
cell transplantation | 68 |
chronic diseases | 67 |
prospective cohort | 67 |
hospital admission | 67 |
staphylococcus aureus | 67 |
body mass | 67 |
critically ill | 66 |
metabolic syndrome | 66 |
high level | 66 |
health status | 66 |
cancer patients | 66 |
infl uenza | 66 |
personal protective | 65 |
rs rs | 65 |
crash risk | 65 |
respiratory disease | 65 |
gestational age | 65 |
antibiotic therapy | 65 |
cohort studies | 65 |
antibiotic resistance | 64 |
significantly higher | 64 |
risk governance | 64 |
will also | 64 |
informed consent | 63 |
pathogenic vtec | 63 |
genetic counseling | 63 |
protective measures | 63 |
global risks | 63 |
confirmed cases | 63 |
per year | 63 |
prospective study | 63 |
large number | 62 |
pandemic risk | 62 |
controlled trials | 62 |
odds ratio | 62 |
african americans | 62 |
risk patients | 62 |
hong kong | 62 |
may occur | 61 |
widely used | 61 |
health literacy | 61 |
see table | 61 |
contact tracing | 61 |
mortality rates | 61 |
peptic ulcer | 61 |
tail risk | 61 |
hematopoietic stem | 61 |
regression analysis | 60 |
law enforcement | 60 |
tourism demand | 60 |
ng ml | 60 |
years old | 60 |
overall risk | 60 |
antimicrobial resistance | 60 |
per day | 60 |
health outcomes | 60 |
cardiovascular events | 59 |
influenza vaccine | 59 |
disease prevention | 59 |
syndrome coronavirus | 59 |
long term | 59 |
may result | 59 |
dairy calves | 59 |
observational studies | 58 |
severe disease | 58 |
general public | 58 |
geopolitical risks | 58 |
sars outbreak | 58 |
environmental factors | 58 |
air pollution | 58 |
future research | 57 |
cardiovascular diseases | 57 |
chronic conditions | 57 |
highest risk | 57 |
will need | 57 |
respiratory distress | 57 |
respiratory infections | 57 |
asthma exacerbations | 56 |
preventive measures | 56 |
health authorities | 56 |
sectional study | 56 |
may increase | 56 |
literature review | 56 |
malaria risk | 56 |
coronary heart | 56 |
scientific opinion | 55 |
confidence intervals | 55 |
health security | 55 |
influenza vaccination | 55 |
older adults | 55 |
drug use | 55 |
correlation coefficient | 55 |
geopolitical risk | 55 |
birth defects | 55 |
contam panel | 55 |
sample size | 54 |
chronic hypertension | 54 |
severe illness | 54 |
patients receiving | 54 |
working group | 54 |
randomised controlled | 54 |
mortality risk | 54 |
flying foxes | 53 |
wide range | 53 |
coronary artery | 53 |
different levels | 53 |
mortality rate | 53 |
different types | 53 |
mean age | 52 |
surveillance systems | 52 |
social isolation | 52 |
observational study | 52 |
critical care | 52 |
transmission risk | 52 |
risk evaluation | 52 |
posted may | 52 |
emerging risks | 52 |
national health | 52 |
greater risk | 52 |
personal responsibility | 52 |
middle east | 52 |
study population | 52 |
present study | 52 |
bone marrow | 52 |
tourism industry | 52 |
natural hazards | 52 |
hendra virus | 51 |
available data | 51 |
data analysis | 51 |
atrial fibrillation | 51 |
health information | 51 |
deep learning | 51 |
retrospective cohort | 51 |
significantly associated | 51 |
regression model | 51 |
tract infections | 51 |
european countries | 51 |
council directive | 51 |
precautionary principle | 51 |
may cause | 51 |
lung transplant | 50 |
disease transmission | 50 |
socioeconomic status | 50 |
early detection | 50 |
related risk | 50 |
significant differences | 50 |
infected patients | 50 |
compliant results | 50 |
welfare conditions | 50 |
disease outbreaks | 50 |
health policy | 50 |
salmonella spp | 50 |
risk category | 50 |
sensitivity analysis | 50 |
distress syndrome | 49 |
risk area | 49 |
immune response | 49 |
occupational risks | 49 |
case reports | 49 |
many countries | 49 |
milk replacer | 48 |
communicable diseases | 48 |
fi rst | 48 |
risk information | 48 |
health emergency | 48 |
health professionals | 48 |
risk areas | 48 |
protective behaviors | 48 |
directive ec | 48 |
risk amplification | 48 |
close contact | 47 |
highly pathogenic | 47 |
risk index | 47 |
new zealand | 47 |
retrospective study | 47 |
potential risks | 47 |
influenza infection | 47 |
united nations | 47 |
biological hazards | 46 |
specific risk | 46 |
risk behaviors | 46 |
exposure assessment | 46 |
clinical features | 46 |
vascular disease | 46 |
test results | 46 |
ill patients | 46 |
results show | 46 |
people living | 46 |
recent studies | 46 |
immunocompromised patients | 46 |
dog food | 46 |
commonly used | 46 |
working conditions | 45 |
health system | 45 |
mechanical ventilation | 45 |
cell lines | 45 |
risk profile | 45 |
european commission | 45 |
million people | 45 |
guarantee network | 45 |
mg kg | 45 |
local authorities | 45 |
prediction models | 45 |
time period | 45 |
epidemiological studies | 45 |
prostate cancer | 44 |
determine whether | 44 |
creative commons | 44 |
significant difference | 44 |
national institute | 44 |
perception accuracy | 44 |
several studies | 44 |
financial system | 44 |
respiratory diseases | 44 |
health systems | 44 |
healthcare system | 44 |
health behavior | 44 |
north america | 44 |
medrxiv preprint | 44 |
hazardous waste | 44 |
herd immunity | 44 |
also found | 44 |
time series | 44 |
based study | 44 |
also important | 44 |
artery disease | 43 |
patients treated | 43 |
fungal infections | 43 |
data set | 43 |
making process | 43 |
cell transplant | 43 |
symptom onset | 43 |
south korea | 43 |
early pregnancy | 43 |
see also | 42 |
task force | 42 |
financial markets | 42 |
among women | 42 |
construction workers | 42 |
care providers | 42 |
incubation period | 42 |
european union | 42 |
physical distancing | 42 |
private sector | 42 |
elevated risk | 42 |
age years | 42 |
health service | 42 |
income countries | 42 |
low birth | 42 |
job loss | 42 |
table shows | 41 |
safety climate | 41 |
suicidal behavior | 41 |
social contact | 41 |
better understand | 41 |
emergency department | 41 |
will continue | 41 |
zoonotic diseases | 41 |
adverse event | 41 |
risk estimates | 41 |
physical health | 41 |
virus disease | 41 |
companion animals | 41 |
member states | 41 |
cognitive decline | 41 |
life sciences | 41 |
physical proximity | 40 |
risk exposures | 40 |
risk managers | 40 |
preterm infants | 40 |
regression models | 40 |
goat production | 40 |
dementia risk | 40 |
urban areas | 40 |
great britain | 40 |
odds ratios | 40 |
mass gatherings | 40 |
one hand | 40 |
future studies | 40 |
occupational diseases | 40 |
social support | 40 |
barr virus | 40 |
patients may | 40 |
risk scores | 40 |
medical conditions | 40 |
control studies | 40 |
hiv aids | 39 |
disease outbreak | 39 |
linear regression | 39 |
poor welfare | 39 |
pregnancy registry | 39 |
direct contact | 39 |
important risk | 39 |
venous thromboembolism | 39 |
inhibitory control | 39 |
chemical hazards | 39 |
authors declare | 39 |
cps systems | 39 |
population density | 39 |
seasonal influenza | 39 |
among individuals | 39 |
reactive protein | 39 |
clinical outcomes | 38 |
economic impact | 38 |
body weight | 38 |
animal experiments | 38 |
risk network | 38 |
two weeks | 38 |
kidney disease | 38 |
cell carcinoma | 38 |
colorectal cancer | 38 |
health hazards | 38 |
human infection | 38 |
older people | 38 |
human immunodeficiency | 38 |
viral infections | 38 |
physical inactivity | 38 |
decision analysis | 38 |
alcohol use | 38 |
inflammatory bowel | 38 |
complex network | 38 |
cognitive function | 38 |
negative impact | 38 |
infectious agents | 38 |
significant association | 38 |
pathogenic avian | 38 |
chronic hepatitis | 38 |
bladder cancer | 37 |
daily risk | 37 |
systematic reviews | 37 |
standard deviation | 37 |
risk levels | 37 |
randomized trial | 37 |
occupational safety | 37 |
immune responses | 37 |
surgical smoke | 37 |
environmental risks | 37 |
medical care | 37 |
monte carlo | 37 |
chemical substances | 37 |
two groups | 37 |
immunodeficiency virus | 37 |
transmission dynamics | 37 |
emergency management | 37 |
human beings | 37 |
signifi cant | 37 |
risk research | 37 |
calves fed | 37 |
assessment tool | 37 |
chain information | 37 |
will help | 37 |
patients taking | 37 |
data available | 37 |
respiratory symptoms | 36 |
synthetic biology | 36 |
deep alm | 36 |
disaster management | 36 |
human transmission | 36 |
economic growth | 36 |
family history | 36 |
chemical residues | 36 |
study design | 36 |
bacterial infections | 36 |
occupational risk | 36 |
blood components | 36 |
patient care | 36 |
rights reserved | 36 |
aged years | 36 |
brain injury | 36 |
borne diseases | 36 |
hepatocellular carcinoma | 36 |
general practice | 36 |
current meat | 36 |
health issues | 36 |
randomized clinical | 36 |
sustainable development | 36 |
trimester exposure | 36 |
management decisions | 36 |
natural disaster | 36 |
open access | 36 |
campylobacter spp | 36 |
risk level | 36 |
health behaviors | 36 |
calf mortality | 36 |
different risk | 36 |
emergency response | 36 |
investment risk | 35 |
risk exposure | 35 |
increased mortality | 35 |
small animal | 35 |
severe cap | 35 |
adverse health | 35 |
mortality among | 35 |
streptococcus pneumoniae | 35 |
social amplification | 35 |
longitudinal study | 35 |
mobile phone | 35 |
supplementary material | 35 |
national level | 35 |
higher levels | 35 |
one health | 35 |
intelligence community | 35 |
stress symptoms | 35 |
veterinary medicine | 35 |
borne disease | 35 |
may reduce | 35 |
distancing measures | 35 |
test result | 35 |
overseas investment | 35 |
crash strategy | 35 |
household agents | 35 |
resistant staphylococcus | 35 |
antenatal risk | 35 |
i will | 34 |
factors may | 34 |
inclusion criteria | 34 |
mild cognitive | 34 |
rejection sensitivity | 34 |
nai treatment | 34 |
medical profession | 34 |
adverse effect | 34 |
recent study | 34 |
precautionary measures | 34 |
global burden | 34 |
farming systems | 34 |
drug users | 34 |
occupational exposure | 34 |
health promotion | 34 |
control practices | 34 |
incidence rates | 34 |
clinical risk | 34 |
environmental risk | 34 |
surveillance system | 34 |
prohibited substances | 34 |
work community | 33 |
small number | 33 |
risks related | 33 |
cell culture | 33 |
antiretroviral therapy | 33 |
mg dl | 33 |
red cell | 33 |
statistical analysis | 33 |
policy makers | 33 |
bowel disease | 33 |
based case | 33 |
national security | 33 |
viral infection | 33 |
producing animals | 33 |
anti biotics | 33 |
third trimester | 33 |
last years | 33 |
infection prevention | 33 |
research study | 33 |
environmental protection | 33 |
liver disease | 33 |
allogeneic hematopoietic | 33 |
scientific evidence | 33 |
septic shock | 33 |
anti biotic | 33 |
clinical course | 33 |
process hygiene | 33 |
times higher | 33 |
high prevalence | 33 |
study period | 33 |
clinical signs | 33 |
data collected | 33 |
high default | 33 |
may affect | 33 |
disease surveillance | 33 |
risk population | 33 |
may require | 33 |
nitric oxide | 33 |
long time | 33 |
flying fox | 33 |
respiratory infection | 33 |
moderate risk | 33 |
decision makers | 33 |
respiratory failure | 33 |
developed countries | 32 |
young children | 32 |
chronic illness | 32 |
real economy | 32 |
social interactions | 32 |
antiretroviral pregnancy | 32 |
many people | 32 |
management strategies | 32 |
individual level | 32 |
case series | 32 |
factor analysis | 32 |
pulmonary disease | 32 |
hiv infection | 32 |
life science | 32 |
animal studies | 32 |
chronic kidney | 32 |
per week | 32 |
patients admitted | 32 |
disease emergence | 32 |
ms risk | 32 |
fatality rate | 32 |
much higher | 32 |
missing data | 32 |
extremely low | 32 |
health emergencies | 32 |
financial institutions | 32 |
based cohort | 32 |
st century | 32 |
human consumption | 32 |
global risk | 32 |
adverse outcomes | 32 |
converting enzyme | 31 |
modifiable risk | 31 |
reduce risk | 31 |
consequential medical | 31 |
sars epidemic | 31 |
early warning | 31 |
study conducted | 31 |
hiv transmission | 31 |
hazard ratio | 31 |
care professionals | 31 |
year follow | 31 |
perceived burdensomeness | 31 |
helicobacter pylori | 31 |
positively associated | 31 |
key benefits | 31 |
diagnostic tests | 31 |
bovine tuberculosis | 31 |
farm level | 31 |
new cases | 31 |
nan doi | 31 |
may help | 31 |
response inhibition | 31 |
main hazards | 31 |
several factors | 31 |
health education | 31 |
well known | 31 |
clinical studies | 31 |
protective effect | 31 |
screening program | 30 |
data sources | 30 |
value tree | 30 |
hazard ratios | 30 |
suicidal ideation | 30 |
west africa | 30 |
social networks | 30 |
low levels | 30 |
advisory committee | 30 |
prediction rule | 30 |
scientific community | 30 |
effective risk | 30 |
chinese stock | 30 |
safety risk | 30 |
high school | 30 |
media coverage | 30 |
relatively low | 30 |
case report | 30 |
case studies | 30 |
surge capacity | 30 |
medical event | 30 |
also reported | 30 |
patients hospitalized | 30 |
east respiratory | 30 |
lower respiratory | 30 |
nervous system | 30 |
first time | 30 |
risk cohort | 30 |
new technologies | 30 |
oxidative stress | 30 |
goat meat | 30 |
first responders | 30 |
significant risk | 30 |
confirmed covid | 30 |
high blood | 30 |
studies suggest | 30 |
emergency preparedness | 30 |
healthcare providers | 30 |
safe chicken | 29 |
patients without | 29 |
participants reported | 29 |
faecal contamination | 29 |
among people | 29 |
african american | 29 |
sheep goats | 29 |
current covid | 29 |
one year | 29 |
diagnostic testing | 29 |
blood transfusion | 29 |
personal risk | 29 |
health research | 29 |
new information | 29 |
heart rate | 29 |
economic development | 29 |
public awareness | 29 |
data sets | 29 |
additional information | 29 |
yellow fever | 29 |
might also | 29 |
congenital malformations | 29 |
toxicological profile | 29 |
sensitivity analyses | 29 |
biological agents | 29 |
may become | 29 |
terrorist attacks | 29 |
gold standard | 29 |
response rate | 29 |
cigarette smoking | 29 |
epidemiological data | 29 |
risk mitigation | 29 |
urinary tract | 29 |
lessons learned | 29 |
health interventions | 29 |
current study | 29 |
herpes zoster | 29 |
cervical cancer | 29 |
first step | 29 |
six months | 29 |
risk among | 29 |
currently available | 29 |
pet food | 29 |
historical data | 29 |
many cases | 29 |
homeland security | 29 |
took place | 29 |
pathogen transmission | 28 |
government agencies | 28 |
emergency risk | 28 |
prevention measures | 28 |
emerging risk | 28 |
better understanding | 28 |
intrusion detection | 28 |
become available | 28 |
primary outcome | 28 |
care worker | 28 |
global supply | 28 |
uric acid | 28 |
pulmonary embolism | 28 |
new data | 28 |
research ethics | 28 |
risk will | 28 |
acute coronary | 28 |
included studies | 28 |
rf radiation | 28 |
control systems | 28 |
dangerous pathogens | 28 |
icu patients | 28 |
may contribute | 28 |
international health | 28 |
particularly important | 28 |
older age | 28 |
children born | 28 |
population based | 28 |
risk categories | 28 |
positive correlation | 28 |
root farm | 28 |
may include | 28 |
business continuity | 28 |
randomized trials | 28 |
average weight | 28 |
drug administration | 28 |
management system | 28 |
psychological impact | 28 |
safety concerns | 28 |
per hour | 28 |
within days | 28 |
significantly lower | 28 |
genetically modified | 28 |
competing interests | 28 |
chronic obstructive | 28 |
pregnancy outcome | 28 |
suicide attempts | 28 |
disease spread | 28 |
short term | 28 |
smoking cessation | 28 |
respiratory syncytial | 28 |
take place | 28 |
pet ownership | 27 |
best practices | 27 |
artificial intelligence | 27 |
rumen development | 27 |
systematic risk | 27 |
decision tree | 27 |
quality assurance | 27 |
visual inspection | 27 |
provide information | 27 |
results suggest | 27 |
visual analytics | 27 |
risk may | 27 |
patients undergoing | 27 |
findings suggest | 27 |
metabolically healthy | 27 |
based approach | 27 |
scientific knowledge | 27 |
global public | 27 |
community identification | 27 |
also includes | 27 |
vast majority | 27 |
risk models | 27 |
marrow transplantation | 27 |
much less | 27 |
care units | 27 |
three main | 27 |
cardiovascular mortality | 27 |
syncytial virus | 27 |
investment risks | 27 |
banking system | 27 |
flock herd | 27 |
closely related | 27 |
health importance | 27 |
obstructive pulmonary | 27 |
calf welfare | 27 |
btb incident | 27 |
risk model | 27 |
financial networks | 27 |
combination therapy | 27 |
clinical data | 27 |
mainland china | 27 |
risk spillover | 27 |
individual risk | 27 |
may vary | 27 |
viral load | 27 |
lung function | 27 |
information technology | 27 |
diabetic retinopathy | 27 |
patients infected | 27 |
land use | 27 |
lung disease | 27 |
total risk | 27 |
chain reaction | 27 |
health conditions | 27 |
mass media | 27 |
thwarted belongingness | 27 |
data suggest | 27 |
will provide | 27 |
antibiotic treatment | 27 |
big data | 27 |
biological risks | 27 |
higher rates | 26 |
general health | 26 |
work environment | 26 |
past years | 26 |
pregnancy outcomes | 26 |
individual patient | 26 |
public risk | 26 |
using data | 26 |
wild animals | 26 |
psychological stress | 26 |
significant effect | 26 |
blood cell | 26 |
detailed ultrasound | 26 |
water quality | 26 |
preterm birth | 26 |
coronavirus pandemic | 26 |
meat safety | 26 |
reduced risk | 26 |
protective factors | 26 |
critical infrastructure | 26 |
risk participants | 26 |
training data | 26 |
will become | 26 |
face masks | 26 |
selection bias | 26 |
validation cohort | 26 |
weight loss | 26 |
inflammatory cytokines | 26 |
major risk | 26 |
american college | 26 |
real time | 26 |
factors influencing | 26 |
will lead | 26 |
negative consequences | 26 |
chronic respiratory | 26 |
acute myocardial | 26 |
ultrasound examination | 26 |
human exposure | 26 |
lopinavir ritonavir | 26 |
average number | 26 |
small ruminant | 25 |
manufacturing processes | 25 |
scientific committee | 25 |
animal cell | 25 |
home orders | 25 |
hazmat suits | 25 |
icu admission | 25 |
air quality | 25 |
presumed consent | 25 |
probability distribution | 25 |
health workers | 25 |
hospitality industry | 25 |
east asia | 25 |
physical system | 25 |
another study | 25 |
greatest risk | 25 |
immune checkpoint | 25 |
solid organ | 25 |
risk regulation | 25 |
medical records | 25 |
urinary antigen | 25 |
per cent | 25 |
industrialized countries | 25 |
risk taking | 25 |
takes place | 25 |
early stage | 25 |
cancer mortality | 25 |
median age | 25 |
among others | 25 |
birth cohort | 25 |
medical services | 25 |
high mortality | 25 |
intervention group | 25 |
human lives | 25 |
infected individuals | 25 |
behavior change | 25 |
protection protocols | 25 |
influenza viruses | 25 |
blood cultures | 25 |
ten years | 25 |
insulin resistance | 25 |
gastrointestinal bleeding | 25 |
stay home | 25 |
scoring system | 25 |
social network | 25 |
economic effects | 25 |
health insurance | 25 |
renal failure | 25 |
operating room | 25 |
hygiene promotion | 25 |
perceived understanding | 25 |
must also | 25 |
relatively high | 25 |
naturally occurring | 25 |
administrative strategy | 25 |
will increase | 25 |
incidence risk | 25 |
healthcare facilities | 25 |
measures taken | 25 |
practice guidelines | 25 |
cerebrovascular disease | 25 |
prospective studies | 25 |
economic risks | 24 |
institutional actors | 24 |
biological weapons | 24 |
increased incidence | 24 |
seeking behavior | 24 |
women aged | 24 |
health measures | 24 |
edible tissues | 24 |
negative effects | 24 |
study showed | 24 |
sectional survey | 24 |
th percentile | 24 |
strongly associated | 24 |
detectable cases | 24 |
public places | 24 |
longitudinal studies | 24 |
may need | 24 |
relative risks | 24 |
electronic health | 24 |
lung injury | 24 |
higher prevalence | 24 |
loan guarantee | 24 |
will require | 24 |
risk horizon | 24 |
independent risk | 24 |
increase risk | 24 |
arterial hypertension | 24 |
pilot study | 24 |
stress disorder | 24 |
smoking status | 24 |
population level | 24 |
related diseases | 24 |
performed using | 24 |
infected animals | 24 |
assessed using | 24 |
significant reduction | 24 |
behavioural risk | 24 |
information regarding | 24 |
bacterial infection | 24 |
risk posed | 24 |
use disorders | 24 |
human disease | 24 |
risk estimation | 24 |
increased prevalence | 24 |
chicken pox | 24 |
systolic blood | 24 |
cyber security | 24 |
value chains | 24 |
well established | 24 |
coping appraisal | 24 |
proton pump | 24 |
among children | 24 |
similar results | 24 |
qualitative study | 24 |
renal function | 24 |
may provide | 24 |
work life | 24 |
health surveillance | 24 |
much lower | 24 |
security measures | 24 |
health consequences | 24 |
issues related | 24 |
middle childhood | 24 |
sheep goat | 24 |
human population | 24 |
risk behavior | 24 |
musculoskeletal disorders | 24 |
ischemic heart | 24 |
mitigation measures | 24 |
southeast asia | 23 |
defence layers | 23 |
decreased risk | 23 |
less common | 23 |
information sources | 23 |
different ways | 23 |
control strategies | 23 |
important factor | 23 |
hazard identification | 23 |
water supply | 23 |
usual care | 23 |
inspection procedures | 23 |
also associated | 23 |
syndromic surveillance | 23 |
years ago | 23 |
platelet count | 23 |
exposure risks | 23 |
care system | 23 |
dark web | 23 |
regression analyses | 23 |
cognitive training | 23 |
study found | 23 |
healthy adults | 23 |
intelligent adversary | 23 |
administrative measures | 23 |
online survey | 23 |
also provide | 23 |
transmission rate | 23 |
pneumococcal pneumonia | 23 |
life cycle | 23 |
negative bacteria | 23 |
adult patients | 23 |
young adults | 23 |
york city | 23 |
hospital admissions | 23 |
ischemic stroke | 23 |
estimated using | 23 |
higher level | 23 |
gi bleeding | 23 |
vice versa | 23 |
special issue | 23 |
medium enterprises | 23 |
systemic inflammation | 23 |
life expectancy | 23 |
risk stratification | 23 |
sewage sludge | 23 |
young calves | 23 |
absolute risk | 23 |
containment measures | 23 |
intelligence communities | 23 |
studies indicate | 23 |
epidemiologic studies | 23 |
serious adverse | 23 |
care facilities | 23 |
care settings | 23 |
growth factor | 23 |
results indicate | 23 |
viral shedding | 23 |
surface water | 23 |
strong recommendation | 23 |
administrative powers | 23 |
zoonotic infections | 23 |
spatially structured | 23 |
polymerase chain | 23 |
expert opinion | 23 |
related stress | 23 |
adherent subjects | 23 |
hearing loss | 23 |
primary prevention | 23 |
hemorrhagic fever | 23 |
risk tolerance | 23 |
public perceptions | 23 |
dual use | 23 |
childhood cancer | 23 |
normal distribution | 23 |
independent variables | 23 |
risk ranking | 23 |
invasive fungal | 22 |
ground water | 22 |
associated infections | 22 |
haemoglobin levels | 22 |
two different | 22 |
case fatality | 22 |
animal diseases | 22 |
key role | 22 |
health impacts | 22 |
human infections | 22 |
make decisions | 22 |
surgical mask | 22 |
research council | 22 |
three months | 22 |
will depend | 22 |
predictive value | 22 |
potential impact | 22 |
limited data | 22 |
pandemic preparedness | 22 |
financial support | 22 |
vulnerable populations | 22 |
scale disaster | 22 |
available online | 22 |
financial crises | 22 |
economic consequences | 22 |
financial risk | 22 |
publicly available | 22 |
lifestyle factors | 22 |
risk locus | 22 |
disease burden | 22 |
positive test | 22 |
th century | 22 |
scale disasters | 22 |
gastrointestinal tract | 22 |
cardio vascular | 22 |
asian countries | 22 |
least two | 22 |
anxiety sensitivity | 22 |
posttraumatic stress | 22 |
literature search | 22 |
structural entropy | 22 |
relatively small | 22 |
treatment options | 22 |
spatial distribution | 22 |
increased risks | 22 |
perceived health | 22 |
medical staff | 22 |
bleeding risk | 22 |
new risks | 22 |
demographic characteristics | 22 |
virus transmission | 22 |
two studies | 22 |
exposure risk | 22 |
influenza incidence | 22 |
bird flu | 22 |
working paper | 22 |
predictor variables | 22 |
clinical presentation | 22 |
educational level | 22 |
outcomes among | 22 |
respiratory viruses | 22 |
painted toys | 22 |
infection rate | 22 |
will likely | 22 |
haemorrhagic fever | 22 |
stock price | 22 |
weight gain | 22 |
health occupations | 22 |
new coronavirus | 22 |
social sector | 22 |
calf farming | 22 |
electromagnetic fields | 22 |
randomly selected | 22 |
real world | 22 |
red meat | 22 |
reproduction number | 22 |
descriptive study | 22 |
family member | 22 |
among men | 22 |
upper gastrointestinal | 22 |
red blood | 21 |
ethnic groups | 21 |
commons licence | 21 |
current pandemic | 21 |
adventure tourism | 21 |
network structure | 21 |
also known | 21 |
resistant bacteria | 21 |
prognostic factors | 21 |
safety assurance | 21 |
chemical mixtures | 21 |
safety measures | 21 |
cancer registry | 21 |
occupational disease | 21 |
renal disease | 21 |
main risk | 21 |
many studies | 21 |
endemic areas | 21 |
adverse reactions | 21 |
platelet transfusion | 21 |
antiviral treatment | 21 |
preventive behaviors | 21 |
leading cause | 21 |
care homes | 21 |
effect sizes | 21 |
negative results | 21 |
significantly increased | 21 |
monitoring programmes | 21 |
international community | 21 |
social systems | 21 |
within hours | 21 |
neutropenic patients | 21 |
human pathogenic | 21 |
personal hygiene | 21 |
narrative review | 21 |
surveillance data | 21 |
also need | 21 |
mitigation strategies | 21 |
high incidence | 21 |
febrile neutropenia | 21 |
us population | 21 |
south america | 21 |
benefit analysis | 21 |
lymph nodes | 21 |
health impact | 21 |
different risks | 21 |
hematopoietic cell | 21 |
across different | 21 |
loved ones | 21 |
risk categorisation | 21 |
first two | 21 |
inspection system | 21 |
basic reproduction | 21 |
inject drugs | 21 |
challenge studies | 21 |
weight infants | 21 |
nrcp testing | 21 |
international business | 21 |
tile test | 21 |
available evidence | 21 |
previous research | 21 |
dependent variable | 21 |
body fluids | 21 |
science research | 21 |
assurance system | 21 |
three times | 21 |
new risk | 21 |
research project | 21 |
among adults | 21 |
people aged | 21 |
hazard analysis | 21 |
elderly patients | 21 |
risk identification | 21 |
operating theatre | 21 |
infectious complications | 21 |
folic acid | 21 |
efsa panel | 21 |
active surveillance | 21 |
risk measures | 21 |
medium potential | 21 |
solid waste | 21 |
medium risk | 21 |
perceived risks | 21 |
risk equations | 21 |
high potential | 21 |
preterm neonates | 20 |
known risk | 20 |
reducing contact | 20 |
reported cases | 20 |
cancer incidence | 20 |
negative feelings | 20 |
two types | 20 |
race ethnicity | 20 |
computed tomography | 20 |
inspection methods | 20 |
palliative care | 20 |
standard errors | 20 |
blood haemoglobin | 20 |
close proximity | 20 |
urgent need | 20 |
hand washing | 20 |
network meta | 20 |
disseminated intravascular | 20 |
ppi therapy | 20 |
high identification | 20 |
factor burden | 20 |
increasing risk | 20 |
credit risk | 20 |
sample sizes | 20 |
inflammatory response | 20 |
organ transplant | 20 |
risk based | 20 |
policy implications | 20 |
balance sheet | 20 |
industrial control | 20 |
google scholar | 20 |
mathematical models | 20 |
large numbers | 20 |
economic crisis | 20 |
natural environment | 20 |
many years | 20 |
preterm delivery | 20 |
endothelial dysfunction | 20 |
human error | 20 |
scientific literature | 20 |
patient population | 20 |
fl uconazole | 20 |
psychological distress | 20 |
studies investigating | 20 |
term outcomes | 20 |
information available | 20 |
pandemic response | 20 |
epidemiological research | 20 |
low level | 20 |
positive impact | 20 |
nursing homes | 20 |
risk individuals | 20 |
anomaly detection | 20 |
stock returns | 20 |
will occur | 20 |
normal development | 20 |
actors involved | 20 |
well understood | 20 |
significant impact | 20 |
safety monitoring | 20 |
safety data | 20 |
renal cell | 20 |
hazards associated | 20 |
dead bodies | 20 |
global warming | 20 |
adolescent brain | 20 |
correlation coefficients | 20 |
fifth guy | 20 |
health regulations | 20 |
risk behaviours | 20 |
established risk | 20 |
factors related | 20 |
sars crisis | 20 |
empirical study | 20 |
international organisations | 20 |
qualitative research | 20 |
singapore government | 20 |
moral hazard | 20 |
one case | 20 |
oxygen saturation | 20 |
higher rate | 20 |
necrosis factor | 20 |
tourism sector | 20 |
outbreak risk | 20 |
study reported | 20 |
people using | 20 |
invasive pneumococcal | 20 |
healthcare settings | 20 |
adjusted hr | 20 |
case patients | 20 |
respiratory infectious | 20 |
year period | 20 |
culture results | 20 |
chronic lung | 20 |
analyzed using | 20 |
statistical analyses | 20 |
negative impacts | 20 |
residue monitoring | 20 |
programmable logic | 20 |
less severe | 20 |
high rates | 20 |
research studies | 20 |
growth rate | 19 |
real estate | 19 |
future generations | 19 |
commons attribution | 19 |
comorbid conditions | 19 |
international travel | 19 |
based model | 19 |
infected cases | 19 |
network analysis | 19 |
swine flu | 19 |
coagulation factors | 19 |
source farms | 19 |
individual behavior | 19 |
blood samples | 19 |
two main | 19 |
tick bites | 19 |
company risk | 19 |
disease activity | 19 |
enteric pathogens | 19 |
injection equipment | 19 |
bite prevention | 19 |
illicit use | 19 |
international tourism | 19 |
health problem | 19 |
antimicrobial therapy | 19 |
ulcer bleeding | 19 |
vascular events | 19 |
multiple factors | 19 |
trailing sample | 19 |
massive transfusion | 19 |
also used | 19 |
news media | 19 |
exchange rate | 19 |
cloud manufacturing | 19 |
evidence suggests | 19 |
companion animal | 19 |
become infected | 19 |
often used | 19 |
risk society | 19 |
market risk | 19 |
west nile | 19 |
saudi arabia | 19 |
mental disorders | 19 |
secondary prevention | 19 |
training group | 19 |
medication use | 19 |
likely due | 19 |
personal protection | 19 |
person transmission | 19 |
internal consistency | 19 |
disease risks | 19 |
well documented | 19 |
five years | 19 |
environmental health | 19 |
effect estimates | 19 |
individuals may | 19 |
neuraminidase inhibitors | 19 |
overall mortality | 19 |
upper respiratory | 19 |
risks posed | 19 |
human services | 19 |
production systems | 19 |
handwashing campaigns | 19 |
immune function | 19 |
older workers | 19 |
tract infection | 19 |
cause harm | 19 |
probability distributions | 19 |
clinically relevant | 19 |
cases reported | 19 |
ethics committee | 19 |
interim guidance | 19 |
among health | 19 |
risky decision | 19 |
crisis communication | 19 |
gram stain | 19 |
i think | 19 |
advanced manufacturing | 19 |
people may | 19 |
study using | 19 |
drug resistance | 19 |
like illness | 19 |
random walk | 19 |
three studies | 19 |
common cause | 19 |
empirical evidence | 19 |
risk methodologies | 19 |
scientific veterinary | 19 |
arterial disease | 19 |
related risks | 19 |
risk communications | 19 |
risk event | 19 |
england high | 19 |
high doses | 19 |
many patients | 19 |
third party | 19 |
different countries | 19 |
central nervous | 19 |
cases per | 19 |
older patients | 19 |
intravascular coagulation | 19 |
one another | 19 |
hazardous events | 19 |
low dose | 19 |
cognitive development | 19 |
heavy metals | 19 |
future risk | 19 |
risk drinkers | 19 |
local health | 19 |
early stages | 19 |
clinical management | 19 |
group members | 19 |
influenza vaccines | 19 |
venous thrombosis | 19 |
hazards identified | 19 |
risk handling | 19 |
effect size | 19 |
hospital stay | 19 |
may explain | 19 |
empirical analysis | 19 |
coronavirus pneumonia | 19 |
host disease | 19 |
studies conducted | 18 |
might lead | 18 |
intellectual property | 18 |
national institutes | 18 |
value chain | 18 |
focus group | 18 |
human populations | 18 |
cell line | 18 |
severe cases | 18 |
multivariate analysis | 18 |
practice guideline | 18 |
national survey | 18 |
remains unclear | 18 |
diastolic blood | 18 |
environ mental | 18 |
contaminated food | 18 |
term care | 18 |
current knowledge | 18 |
increasing number | 18 |
iron deficiency | 18 |
low identification | 18 |
expert assessment | 18 |
put forward | 18 |
learning applications | 18 |
human extinction | 18 |
without permission | 18 |
potential confounders | 18 |
mortality associated | 18 |
fed milk | 18 |
drug interactions | 18 |
negative affect | 18 |
control subjects | 18 |
becoming infected | 18 |
disease incidence | 18 |
level iii | 18 |
high quality | 18 |
portfolio optimization | 18 |
european society | 18 |
phone use | 18 |
pca patients | 18 |
near future | 18 |
study also | 18 |
us government | 18 |
term risk | 18 |
testicular cancer | 18 |
systematic benefit | 18 |
year old | 18 |
four weeks | 18 |
beneficial effects | 18 |
congestive heart | 18 |
foodborne pathogens | 18 |
borne transmission | 18 |
oral therapy | 18 |
risk premium | 18 |
health records | 18 |
sample period | 18 |
particular attention | 18 |
social risks | 18 |
health concern | 18 |
treat patients | 18 |
information provided | 18 |
reuse allowed | 18 |
control programmes | 18 |
disease progression | 18 |
chronic health | 18 |
systematic literature | 18 |
antibiotic prophylaxis | 18 |
mm hg | 18 |
rapid review | 18 |
crowd density | 18 |
viet nam | 18 |
organic solvents | 18 |
extremely preterm | 18 |
dengue fever | 18 |
global pandemic | 18 |
undesirable substances | 18 |
taking place | 18 |
neonatal intensive | 18 |
asset returns | 18 |
fold increased | 18 |
cps security | 18 |
high degree | 18 |
research agenda | 18 |
dental caries | 18 |
limited number | 18 |
pylori eradication | 18 |
future infectiousness | 18 |
risk measure | 18 |
latin america | 18 |
disaster reduction | 18 |
many factors | 18 |
cannabis use | 18 |
healthy people | 18 |
independently associated | 18 |
studies reported | 18 |
cox proportional | 18 |
recent data | 18 |
unclear whether | 18 |
health benefits | 18 |
close contacts | 18 |
risk task | 18 |
potential benefits | 18 |
relative intensity | 18 |
significant associations | 18 |
passive smoking | 18 |
two decades | 18 |
global value | 18 |
communicable disease | 18 |
childhood asthma | 18 |
rheumatic disorders | 18 |
statistical significance | 18 |
btb incidents | 18 |
moderate recommendation | 18 |
life course | 18 |
veterinary surgeons | 18 |
kg day | 18 |
fully adjusted | 18 |
coping strategies | 18 |
cvd risk | 18 |
coronavirus infection | 18 |
current situation | 18 |
preventable diseases | 18 |
level i | 18 |
every year | 18 |
daily dose | 18 |
negative outcomes | 18 |
diseases society | 18 |
electronic supplementary | 18 |
autoimmune diseases | 18 |
recent job | 18 |
allowed without | 18 |
health indicators | 18 |
study risk | 18 |
serum albumin | 18 |
making decisions | 18 |
proportional hazards | 18 |
social determinants | 18 |
potential health | 18 |
brain development | 18 |
publication norms | 18 |
national research | 18 |
contaminated dog | 18 |
risk threshold | 17 |
falciparum malaria | 17 |
cord blood | 17 |
various factors | 17 |
classifi cation | 17 |
eff ective | 17 |
empirical data | 17 |
incident dementia | 17 |
postmenopausal women | 17 |
blood culture | 17 |
risks may | 17 |
specific information | 17 |
another important | 17 |
detailed information | 17 |
calf rearing | 17 |
human behavior | 17 |
college students | 17 |
global level | 17 |
oral health | 17 |
among hws | 17 |
global catastrophe | 17 |
depressed mood | 17 |
cytokine storm | 17 |
different methods | 17 |
management practices | 17 |
ad hoc | 17 |
medicinal products | 17 |
case basis | 17 |
antenatal complications | 17 |
natural history | 17 |
noncommunicable diseases | 17 |
fatty acids | 17 |
two cases | 17 |
occupational injuries | 17 |
human challenge | 17 |
special attention | 17 |
belief model | 17 |
red cells | 17 |
disease management | 17 |
submitted work | 17 |
waste management | 17 |
factors among | 17 |
municipal solid | 17 |
air travel | 17 |
among different | 17 |
chicken consumption | 17 |
care services | 17 |
knowledge base | 17 |
disaster preparedness | 17 |
multiple regression | 17 |
risk disease | 17 |
positive patients | 17 |
fold increase | 17 |
factor model | 17 |
health survey | 17 |
social science | 17 |
mortem examination | 17 |
dependent risk | 17 |
will vary | 17 |
health belief | 17 |
decision support | 17 |
adult population | 17 |
general practitioner | 17 |
working hours | 17 |
facility managers | 17 |
per capita | 17 |
risk awareness | 17 |
infections may | 17 |
environmental conditions | 17 |
biomedical research | 17 |
prediction model | 17 |
significantly different | 17 |
health professional | 17 |
negative effect | 17 |
water body | 17 |
dose aspirin | 17 |
perinatal risk | 17 |
type ii | 17 |
scada systems | 17 |
epidemic risk | 17 |
genetic variants | 17 |
pneumococcal disease | 17 |
broad range | 17 |
ejection fraction | 17 |
data source | 17 |
increased cardiovascular | 17 |
cell transfusion | 17 |
rapidly evolving | 17 |
traumatic brain | 17 |
use diversity | 17 |
severe outcomes | 17 |
calves housed | 17 |
healthcare assistance | 17 |
economic losses | 17 |
differentiated risk | 17 |
evidence base | 17 |
ed risk | 17 |
random sample | 17 |
current risk | 17 |
epidemiological study | 17 |
third countries | 17 |
attitudes towards | 17 |
care systems | 17 |
regional level | 17 |
level ii | 17 |
cyber physical | 17 |
bacillus anthracis | 17 |
health crisis | 17 |
quantitative risk | 17 |
critical interventions | 17 |
new types | 17 |
health organisation | 17 |
current smoking | 17 |
elderly people | 17 |
health data | 17 |
central bank | 17 |
uk biobank | 17 |
social factors | 17 |
emerging infections | 17 |
hygiene measures | 17 |
ionizing radiation | 17 |
rural areas | 17 |
may improve | 17 |
actual risk | 17 |
external validation | 17 |
random effect | 17 |
infant mortality | 17 |
local government | 17 |
antiviral therapy | 17 |
oral anticoagulants | 17 |
severe community | 17 |
public policy | 17 |
health concerns | 17 |
chain management | 17 |
crisis response | 17 |
cloud computing | 17 |
ethical issues | 17 |
environmental quality | 17 |
iii evidence | 17 |
disruption strategies | 17 |
disaster risks | 17 |
lower level | 17 |
major public | 17 |
throat swabs | 17 |
publication bias | 17 |
first months | 17 |
risk due | 17 |
th april | 17 |
routine use | 17 |
increasing age | 17 |
first years | 17 |
fox populations | 17 |
compliant samples | 17 |
world bank | 17 |
resistance genes | 16 |
community transmission | 16 |
upper limit | 16 |
first three | 16 |
admission decision | 16 |
vaccine efficacy | 16 |
protective behavior | 16 |
nile virus | 16 |
severe depressive | 16 |
saharan africa | 16 |
among participants | 16 |
also include | 16 |
marrow transplant | 16 |
elevated levels | 16 |
pulmonary hemorrhage | 16 |
time periods | 16 |
springer nature | 16 |
cardiovascular outcomes | 16 |
protection agency | 16 |
zoster virus | 16 |
calculated using | 16 |
endothelial cells | 16 |
index case | 16 |
left ventricular | 16 |
expected return | 16 |
descriptive statistics | 16 |
ulcer disease | 16 |
white blood | 16 |
also called | 16 |
interquartile range | 16 |
care setting | 16 |
varying degrees | 16 |
risk related | 16 |
may differ | 16 |
twice daily | 16 |
factor variables | 16 |
hospital death | 16 |
study sample | 16 |
analysis showed | 16 |
malformation rate | 16 |
risk spillovers | 16 |
human cases | 16 |
veterinary profession | 16 |
also identified | 16 |
default risk | 16 |
antihypertensive therapy | 16 |
deep neural | 16 |
respiratory illness | 16 |
life events | 16 |
propensity score | 16 |
animal veterinary | 16 |
magnetic resonance | 16 |
nuclear power | 16 |
causing damages | 16 |
current state | 16 |
oxide synthase | 16 |
next section | 16 |
information seeking | 16 |
factors affecting | 16 |
several countries | 16 |
study group | 16 |
cow disease | 16 |
point scale | 16 |
patients requiring | 16 |
risk methodology | 16 |
recent research | 16 |
incidence rate | 16 |
explanatory variables | 16 |
prediction tools | 16 |
five studies | 16 |
bio watch | 16 |
outbreak risks | 16 |
severe sepsis | 16 |
data regarding | 16 |
relevant information | 16 |
condomless sex | 16 |
lower mortality | 16 |
lesser extent | 16 |
different aspects | 16 |
increased susceptibility | 16 |
observation period | 16 |
institutional affiliations | 16 |
will affect | 16 |
veterinary professionals | 16 |
group housing | 16 |
minimally invasive | 16 |
age categories | 16 |
respiratory virus | 16 |
early life | 16 |
studies show | 16 |
native dutch | 16 |
getting infected | 16 |
addictive behavior | 16 |
source attribution | 16 |
warning systems | 16 |
perceived seriousness | 16 |
potentially modifiable | 16 |
chinese center | 16 |
human herpesvirus | 16 |
manufacturing technologies | 16 |
physical attacks | 16 |
social care | 16 |
extended periods | 16 |
teaching hospital | 16 |
public trust | 16 |
mad cow | 16 |
exposure parameters | 16 |
fungal infection | 16 |
disease caused | 16 |
becomes available | 16 |
among workers | 16 |
patient characteristics | 16 |
old age | 16 |
one third | 16 |
endemic area | 16 |
international society | 16 |
ixodes scapularis | 16 |
patient data | 16 |
based models | 16 |
across countries | 16 |
risk estimate | 16 |
growth restriction | 16 |
infected pneumonia | 16 |
important age | 16 |
feed materials | 16 |
global scale | 16 |
risk attitudes | 16 |
management options | 16 |
opportunistic infections | 16 |
milk replacers | 16 |
baseline characteristics | 16 |
good health | 16 |
corresponding author | 16 |
young people | 16 |
studies involving | 16 |
mainly due | 16 |
plasma concentrations | 16 |
later life | 16 |
use research | 16 |
significant increase | 16 |
identifi ed | 16 |
individual differences | 16 |
van den | 16 |
infected pregnant | 16 |
severe hypertension | 16 |
human interventions | 16 |
urgent care | 16 |
neuropsychiatric symptoms | 16 |
european agency | 16 |
univariate analysis | 16 |
methods used | 16 |
negatively impact | 16 |
starting point | 16 |
plasmodium falciparum | 16 |
healthy individuals | 16 |
safety risks | 16 |
social interaction | 16 |
global economic | 16 |
financial market | 16 |
three groups | 16 |
assessment model | 16 |
loss function | 16 |
psychosocial factors | 16 |
mean score | 16 |
will take | 16 |
primary principles | 16 |
preventive behavior | 16 |
also play | 16 |
first days | 16 |
tourism companies | 16 |
gof experiments | 16 |
positive effect | 16 |
also considered | 16 |
whenever possible | 16 |
perinatal outcomes | 16 |
infected individual | 15 |
infected living | 15 |
remains neutral | 15 |
important part | 15 |
comparative data | 15 |
economic models | 15 |
kindergarten readiness | 15 |
meat products | 15 |
mycobacterium bovis | 15 |
factors including | 15 |
specific mortality | 15 |
allergic diseases | 15 |
carcass level | 15 |
nucleic acid | 15 |
significantly reduced | 15 |
three different | 15 |
hsct recipients | 15 |
health agencies | 15 |
human activities | 15 |
service providers | 15 |
influenza epidemics | 15 |
heavily contaminated | 15 |
animal species | 15 |
quarantine recommendations | 15 |
higher incidence | 15 |
farm animals | 15 |
exposure prophylaxis | 15 |
worse outcomes | 15 |
without dementia | 15 |
empirical studies | 15 |
integral part | 15 |
first week | 15 |
chest ct | 15 |
first year | 15 |
time spent | 15 |
per million | 15 |
case control | 15 |
data may | 15 |
comprehensive review | 15 |
excess risk | 15 |
cross sectional | 15 |
slaughter hygiene | 15 |
also occur | 15 |
antifungal prophylaxis | 15 |
causal association | 15 |
animal husbandry | 15 |
nature remains | 15 |
readily available | 15 |
generating procedures | 15 |
pseudomonas aeruginosa | 15 |
antiplatelet therapy | 15 |
three types | 15 |
four times | 15 |
cell counts | 15 |
outcome data | 15 |
modelling study | 15 |
patients using | 15 |
every day | 15 |
goat carcasses | 15 |
risk control | 15 |
risk events | 15 |
become increasingly | 15 |
cumulative incidence | 15 |
pump inhibitors | 15 |
high frequency | 15 |
cryptosporidium parvum | 15 |
states parties | 15 |
behavioral change | 15 |
iso iec | 15 |
fetal outcomes | 15 |
retrospective studies | 15 |
veal calf | 15 |
major natural | 15 |
portfolio selection | 15 |
risk zone | 15 |
pandemic will | 15 |
incremental approach | 15 |
also increase | 15 |
interest rate | 15 |
checkpoint inhibitors | 15 |
influenza season | 15 |
sickle cell | 15 |
disordered eating | 15 |
scientific research | 15 |
ethnic minorities | 15 |
acute lung | 15 |
random effects | 15 |
interaction term | 15 |
causal relationship | 15 |
mass gathering | 15 |
malaria areas | 15 |
posted august | 15 |
false negative | 15 |
food standards | 15 |
positively correlated | 15 |
information asymmetry | 15 |
eye protection | 15 |
ibd patients | 15 |
last two | 15 |
work shift | 15 |
resistant pathogens | 15 |
recent findings | 15 |
part i | 15 |
mg daily | 15 |
published maps | 15 |
intended use | 15 |
eating disorders | 15 |
herd level | 15 |
staff members | 15 |
peripheral arterial | 15 |
genetic factors | 15 |
see section | 15 |
susceptible individuals | 15 |
radical prostatectomy | 15 |
death due | 15 |
surgical masks | 15 |
environmental contamination | 15 |
sexual risk | 15 |
lowest risk | 15 |
lymphocyte ratio | 15 |
cardiac surgery | 15 |
chronic condition | 15 |
multicenter study | 15 |
diabetic patients | 15 |
effi cacy | 15 |
fat mass | 15 |
diff erent | 15 |
risk framework | 15 |
coronary syndrome | 15 |
tobacco smoke | 15 |
posted september | 15 |
large scale | 15 |
health significance | 15 |
calf production | 15 |
contingency plans | 15 |
heightened risk | 15 |
global spread | 15 |
risk populations | 15 |
research methods | 15 |
inflammatory drugs | 15 |
communication activities | 15 |
potential adverse | 15 |
cancer screening | 15 |
white veal | 15 |
pulmonary edema | 15 |
asymptomatic people | 15 |
sars coronavirus | 15 |
vaccine uptake | 15 |
many different | 15 |
different groups | 15 |
blood products | 15 |
virus infections | 15 |
mental illness | 15 |
patients aged | 15 |
make sure | 15 |
broad occupational | 15 |
interest rates | 15 |
behaviors among | 15 |
face mask | 15 |
invasive ventilation | 15 |
substantially higher | 15 |
higher probability | 15 |
total population | 15 |
small sample | 15 |
ai research | 15 |
heart association | 15 |
risk difference | 15 |
complex networks | 15 |
mucous membranes | 15 |
advisory group | 15 |
south african | 15 |
multivariate logistic | 15 |
jurisdictional claims | 15 |
future pandemics | 15 |
two years | 15 |
total cholesterol | 15 |
disease among | 15 |
dengue virus | 15 |
analog risk | 15 |
new hazards | 15 |
among healthcare | 15 |
flocks herds | 15 |
traumatic stress | 15 |
studies using | 15 |
based system | 15 |
balloon analog | 15 |
integrated surveillance | 15 |
term exposure | 15 |
search behavior | 15 |
children aged | 15 |
behavioural surveillance | 15 |
immunization practices | 15 |
hsct patients | 15 |
higher scores | 15 |
var thresholds | 15 |
restaurant industry | 15 |
human papillomavirus | 15 |
select agents | 15 |
serum uric | 15 |
final model | 14 |
based analysis | 14 |
may play | 14 |
next years | 14 |
physical examination | 14 |
economic loss | 14 |
null hypothesis | 14 |
american society | 14 |
international spread | 14 |
public transport | 14 |
human resources | 14 |
gene transfer | 14 |
throw away | 14 |
dog bites | 14 |
malaria prevention | 14 |
among young | 14 |
associated risk | 14 |
previously reported | 14 |
day quarantine | 14 |
longitudinal research | 14 |
possible risk | 14 |
rates among | 14 |
lifestyle risk | 14 |
mental model | 14 |
negligible potential | 14 |
risk domain | 14 |
borrelia burgdorferi | 14 |
transmission among | 14 |
existing literature | 14 |
radiation therapy | 14 |
regarding risk | 14 |
various types | 14 |
formation mechanism | 14 |
critical role | 14 |
highly correlated | 14 |
fault tree | 14 |
agricultural land | 14 |
also asked | 14 |
suspected cases | 14 |
institutional review | 14 |
large proportion | 14 |
government response | 14 |
containment level | 14 |
cognitive biases | 14 |
several reasons | 14 |
risk matrix | 14 |
world war | 14 |
decisions regarding | 14 |
strong association | 14 |
england low | 14 |
three years | 14 |
antibody tests | 14 |
potential consequences | 14 |
multiple degree | 14 |
infected persons | 14 |
viral transmission | 14 |
sheep liver | 14 |
help us | 14 |
contracting covid | 14 |
also likely | 14 |
studies showed | 14 |
analysis methods | 14 |
socioeconomic factors | 14 |
chest rt | 14 |
growth promoters | 14 |
food production | 14 |
will discuss | 14 |
nursing home | 14 |
assistance model | 14 |
must take | 14 |
may change | 14 |
target range | 14 |
preventive measure | 14 |
infection rates | 14 |
laboratory testing | 14 |
data extraction | 14 |
level risk | 14 |
years later | 14 |
health facilities | 14 |
main public | 14 |
less risk | 14 |
vary across | 14 |
gout flares | 14 |
model based | 14 |
self help | 14 |
cause mortality | 14 |
outcome measures | 14 |
provide care | 14 |
outdoor workers | 14 |
current evidence | 14 |
new infectious | 14 |
financial network | 14 |
ovarian cancer | 14 |
younger age | 14 |
note springer | 14 |
van der | 14 |
tick bite | 14 |
reference group | 14 |
also included | 14 |
labor force | 14 |
information systems | 14 |
unwelcome events | 14 |
low incidence | 14 |
animal feed | 14 |
may reflect | 14 |
safety authority | 14 |
free rate | 14 |
patient groups | 14 |
new challenges | 14 |
random variable | 14 |
management systems | 14 |
studies investigated | 14 |
emerging studies | 14 |
higher among | 14 |
four categories | 14 |
health agency | 14 |
exposure time | 14 |
future work | 14 |
systemically important | 14 |
smart grid | 14 |
genetic engineering | 14 |
general practitioners | 14 |
million deaths | 14 |
emerging economies | 14 |
resource allocation | 14 |
local level | 14 |
section iii | 14 |
global governance | 14 |
standard precautions | 14 |
risks perceived | 14 |
physical security | 14 |
study aimed | 14 |
linear model | 14 |
annual report | 14 |
classification system | 14 |
scientific expertise | 14 |
representative sample | 14 |
study included | 14 |
quantitative assessment | 14 |
economic status | 14 |
global financial | 14 |
large cohort | 14 |
conditional autoregression | 14 |
may pose | 14 |
ppe use | 14 |
outpatient treatment | 14 |
second wave | 14 |
platelet transfusions | 14 |
complex systems | 14 |
screening interval | 14 |
four studies | 14 |
study among | 14 |
high rate | 14 |
early childhood | 14 |
care patients | 14 |
learning methods | 14 |
health department | 14 |
travel history | 14 |
may take | 14 |
risk mitigating | 14 |
three major | 14 |
social contract | 14 |
available resources | 14 |
bloodstream infections | 14 |
research involving | 14 |
among pregnant | 14 |
although many | 14 |
different industries | 14 |
significant positive | 14 |
clinical decision | 14 |
ethical standards | 14 |
study aims | 14 |
numerical risk | 14 |
underlying disease | 14 |
respiratory complaints | 14 |
related complications | 14 |
much smaller | 14 |
limited resources | 14 |
using different | 14 |
women exposed | 14 |
five times | 14 |
various forms | 14 |
nationwide cohort | 14 |
major concern | 14 |
death rate | 14 |
normal weight | 14 |
particulate matter | 14 |
ii evidence | 14 |
poor health | 14 |
network models | 14 |
polychlorinated biphenyls | 14 |
adult inpatients | 14 |
slaughterhouse level | 14 |
prefrontal cortex | 14 |
cost per | 14 |
related research | 14 |
several limitations | 14 |
sexually transmitted | 14 |
serum urate | 14 |
medical personnel | 14 |
i evidence | 14 |
low concentrations | 14 |
like sars | 14 |
skin test | 14 |
pharmaceutical interventions | 14 |
brain cognitive | 14 |
varicella pneumonia | 14 |
coronavirus outbreak | 14 |
frequently reported | 14 |
year study | 14 |
clinical settings | 14 |
animal origin | 14 |
high perceived | 14 |
published data | 14 |
pertussis vaccine | 14 |
invasive procedures | 14 |
excessive alcohol | 14 |
important factors | 14 |
injection drug | 14 |
ethnic minority | 14 |
psychiatric disorders | 14 |
new approach | 14 |
observed among | 14 |
road traffic | 14 |
housed calves | 14 |
study will | 14 |
deliberative process | 14 |
intelligence agencies | 14 |
medical devices | 14 |
tested positive | 14 |
may influence | 14 |
mi max | 14 |
continuous variables | 14 |
disease patients | 14 |
angiotensin ii | 14 |
protection motivation | 14 |
pregnancy hypertension | 14 |
consent argument | 14 |
principal component | 14 |
conceptual framework | 14 |
media attention | 14 |
costs associated | 14 |
casecontrol study | 13 |
many risk | 13 |
healthcare personnel | 13 |
lupus erythematosus | 13 |
sec filings | 13 |
secondary bacterial | 13 |
critical illness | 13 |
search terms | 13 |
posted july | 13 |
asymptomatic patients | 13 |
physical exercise | 13 |
studies found | 13 |
genetic risk | 13 |
significantly less | 13 |
risk measurement | 13 |
back pain | 13 |
pandemic planning | 13 |
country clusters | 13 |
careful consideration | 13 |
asset pricing | 13 |
fetal growth | 13 |
among adolescents | 13 |
vital signs | 13 |
weather events | 13 |
manufacturing sector | 13 |
cox regression | 13 |
milk substitute | 13 |
health behaviour | 13 |
trial data | 13 |
malaria transmission | 13 |
public perception | 13 |